GlaxoSmithKline, announced Tuesday that Emma Walmsley, current head of the company's consumer healthcare division, will succeed CEO Andrew Witty when he retires on March 31, 2017. GlaxoSmithKline indicated that Walmsley, who joined the drugmaker in 2010 from L’Oreal, will join the board of directors at the start of next year..
Earlier this year, GlaxoSmithKline announced that Witty would retire in 2017, having served as chief executive since 2008. Internal candidates suggested as possible replacements included Walmsley and Abbas Hussain, head of the company's pharmaceuticals business, as well as chief financial officer Simon Dingemans
Commenting on the appointment, GlaxoSmithKline chairman Philip Hampton remarked "Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare."
Walmsley previously served as president of the company's consumer healthcare unit.
The Wall Street Journal, Bloomberg, International New York Times, MarketWatch, GlaxoSmithKline, BBC News, Financial Times, The Telegraph)
By Matthew Dennis
0 comentários:
Postar um comentário